Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, Louis, Fujioka, Ken, Aroda, Vanita, Chen, Kim, Halseth, Amy, Kesty, Nicole C., Burns, Colleen, Lush, Cameron W. +1 more·2007·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2006-2003

Cited by (178)

Items 101–178 of 178

  1. Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects
    Kim Henriksen, Karen Broekhuizen, Wadim M. I. de Boon, M.A. Karsdal, Asger Reinstrup Bihlet, Claus Christiansen, Marlous R. Dillingh, Marieke de Kam, Raj Kumar, Jacobus Burggraaf et al. · 2021 · British Journal of Clinical Pharmacology
  2. Salmon Calcitonin Attenuates Some Behavioural Responses to Nicotine in Male Mice
    Cajsa Aranäs, Jesper Vestlund, Sarah Witley, Christian E. Edvardsson, Aimilia Lydia Kalafateli, Elisabet Jerlhag · 2021 · Frontiers in Pharmacology
  3. Pharmacotherapy for obesity
    Lisa M. Neff, Louis J. Aronne · 2007 · Current Atherosclerosis Reports
  4. The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action
    Nina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, M.A. Karsdal, Kim Henriksen · 2020 · Journal of Pharmacology and Experimental Therapeutics
  5. Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
    Simone Anna Melander, Anna Katri, M.A. Karsdal, Kim Henriksen · 2022 · European Journal of Pharmacology
  6. Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss
    Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, M.A. Karsdal, Kim Henriksen · 2020 · Journal of Pharmacology and Experimental Therapeutics
  7. Glycomacropeptide Impacts Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, and the Fecal Microbiome in Obese Postmenopausal Women
    Karen E. Hansen, Sangita G. Murali, Ibrahim Zúñiga-Chaves, Garret Suen, Denise Marie Ney · 2023 · Journal of Nutrition
  8. Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure
    Thomas A. Lutz · 2016 · International Journal of Obesity Supplements
  9. Weight-Loss Pharmacotherapy: A Brief Review
    Mary Margaret Huizinga · 2007 · Clinical Diabetes
  10. Obesity
    Samuel Klein, Johannes Anthonius Romijn · 2016 · Elsevier eBooks
  11. Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention
    Emir M. Muzurović, Siniša Dragnić, Sanja Medenica, Brigita Smolović, Predrag Bulajić, Dimitri P. Mikhailidis · 2020 · Journal of Diabetes and its Complications
  12. Approaches to the pharmacological treatment of obesity
    Victoria Salem, Stephen Robert Bloom · 2009 · Expert Review of Clinical Pharmacology
  13. Visceral Adiposity, Insulin Resistance, and Type 2 Diabetes
    Michelle L. Griffith, Lisa M. Younk, Stephen N. Davis · 2010 · American Journal of Lifestyle Medicine
  14. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control
    Ellen E. Ladenheim · 2012 · Current Opinion in Endocrinology Diabetes and Obesity
  15. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats
    Lauren Michelle Stein, Lauren E. McGrath, Rinzin Lhamo, Kieran Koch‐Laskowski, Samantha M. Fortin, Jolanta Skarbaliene, Tamara Baader-Pagler, Rasmus Just, Matthew R. Hayes, Elizabeth G. Mietlicki‐Baase · 2021 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  16. Plasma Amylin and Cognition in Diabetes in the Absence and the Presence of Insulin Treatment
    Wei Qiao Qiu · 2014 · Journal of Diabetes & Metabolism
  17. Hormone-based therapies in the regulation of fuel metabolism and body weight
    Nicole C. Kesty, Jonathan David Roth, David G. Maggs · 2008 · Expert Opinion on Biological Therapy
  18. Food intake and meal pattern in IAPP knockout mice with and without infusion of exogenous IAPP
    M. Olsson, M. Herrington, R. Reidelberger, J. Permert, S. Gebre-Medhin, U. Arnelo · 2012 · Scandinavian Journal of Gastroenterology
  19. Optimizing Diabetes Treatment Using an Amylin Analogue
    Steven V. Edelman · 2008 · The Science of Diabetes Self-Management and Care
  20. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C
    Manuela Giansanti, Antonio De Gabrieli, Salvatore Pasquale Prete, Tiziana Ottone, Maria Domenica Divona, Terry Karimi, Fabio Ciccarone, Maria Teresa Voso, Grazia Graziani, Isabella Faraoni · 2021 · Journal of Pharmacology and Experimental Therapeutics
  21. Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes
    Alan J. Garber · 2015 · Endocrine Practice
  22. Amylin in vasodilation, energy expenditure and inflammation
    Fan Yang · 2014 · Frontiers in bioscience
  23. The protective effect of Azadirachta excelsa leaves extract and quercetin treatment on the learning and memory impairments in relation with insulin and amylin levels in the brain of streptozotocin-induced diabetic rats
    Noor Syaffinaz Noor Mohamad Zin, Nooraain Hashim, Nurdiana Samsulrizal, Nur Syimal’ain Azmi · 2018 · Journal of King Saud University - Science
  24. Long-acting amylin analogue for weight reduction
    Kishore M Gadde, David B. Allison · 2021 · The Lancet
  25. Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs
    Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh · 2013 · Journal of Pharmacy and Nutrition Sciences
  26. Pharmacologic management of obesity
    Robert F. Kushner · 2011 · Pediatric Blood & Cancer
  27. Pharmacotherapy for chronic obesity management: a look into the future
    Mariana Abdel-Malek, Lisa Y. Yang, Alexander Dimitri Miras · 2023 · Internal and Emergency Medicine
  28. Iatrogenic Obesity
    Rekha B. Kumar, Louis J. Aronne · 2020 · Endocrinology and Metabolism Clinics of North America
  29. Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
    Mokhtar Saeed Rejili, Md Sadique Hussain, Yumna Khan, Faouzi Haouala, Subbulakshmi Ganesan, Samir Sahoo, Amrita Pal, Vimal Arora · 2025 · Vascular Pharmacology
  30. Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
    Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward John Pratt · 2026 · Diabetes Obesity and Metabolism
  31. Farmakoterapia otyłości — obecny stan wiedzy
    Beata Matyjaszek‐Matuszek, Aneta Szafraniec, Dominik Porada · 2018 · Endokrynologia Polska
  32. Effects of pramlintide on energy intake and food preference in rats given a choice diet
    Katherine A. Kern, Adrianne M. DiBrog, Johnathan T. Przybysz, Elizabeth G. Mietlicki‐Baase · 2021 · Physiology & Behavior
  33. Amylin analogs for the treatment of obesity without diabetes: present and future
    Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Νικόλαος Παπάνας · 2024 · Expert Review of Clinical Pharmacology
  34. Amylin Level and Gastric Emptying in Obese Children : Before and after Weight Loss
    Omnia F. El-Rasheidy, Dina Amin Saleh, Hala Abdalrahman Ahmed · 2012 · Journal of the Egyptian Society of Parasitology
  35. Current and Future Medical Treatment of Obesity
    Devika Umashanker, Leon I. Igel, Rekha B. Kumar, Louis J. Aronne · 2017 · Gastrointestinal Endoscopy Clinics of North America
  36. Modeling energy intake and body weight effects of a long-acting amylin analogue
    Annika Brings, Jens Markus Borghardt, Jolanta Skarbaliene, Tamara Baader-Pagler, Maria A. Deryabina, Wolfgang Rist, Stefan Scheuerer · 2017 · Journal of Pharmacokinetics and Pharmacodynamics
  37. Targeting the Enteroendocrine System for Treatment of Obesity
    Emily L. Miedzybrodzka, Fiona Mary Gribble, Frank M. Reimann · 2022 · Handbook of experimental pharmacology
  38. Pharmacotherapy for obesity: a field in crisis?
    Wiebke Kristin Fenske, Jennifer Parker, Stephen Robert Bloom · 2011 · Expert Review of Endocrinology & Metabolism
  39. Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer’s Disease in a Mouse Model
    Hana Na, Hua Tian, Zheng-Rong Zhang, Qiang Li, Jack B. Yang, Liam Mcparland, Qini Gan, Wei Q. Qiu · 2021 · American Journal of Alzheimers Disease & Other Dementias
  40. A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
    Michael T. Jacobsen, Christian Poulsen, Katharina L. Kopp, Jørgen Olsen, Nick Cox · 2025 · Peptide Science
  41. Obesity
    Samuel Klein, Elisa Fabbrini, Johannes Anthonius Romijn · 2011 · Elsevier eBooks
  42. Promising areas of pharmacotherapy for obesity
    М. A. Druzhilov, Т. Yu. Kuznetsova, Galina A. Chumakova · 2021 · Russian Journal of Cardiology
  43. Steve Woods's contribution to research on amylin's eating inhibitory effect.
    T. Lutz · 2011 · Physiology and Behavior
  44. The Central Question of Type 2 Diabetes
    Thaïs Rouquet, Marion S. Bonnet, Pierre Clément, Michel Dallaporta, Jean‐Denis Troadec, Julien Roux, Bruno Bariohay · 2013 · Pharmaceutical Patent Analyst
  45. Pramlintide: profile of an amylin analog
    Harold E. Lebovitz · 2012 · Expert Review of Endocrinology & Metabolism
  46. Chronic pramlintide decreases feeding via a reduction in meal size in male rats
    Katherine A. Kern, Adrianne M. DiBrog, Kiran Kaur, Johnathan T. Przybysz, Elizabeth G. Mietlicki‐Baase · 2024 · Peptides
  47. Medical Management of Obesity as it Affects Reflux
    James D. Haddad, Shawn L. Shah · 2021 · Foregut The Journal of the American Foregut Society
  48. Investigating the Physiologic Role of Leptin and Its Relationship to Obesity
    Mohammed Kallash, William H. Frishman · 2025 · Cardiology in Review
  49. Insulin, other hypoglycemic drugs, and glucagon
    Renee C. Page · 2010 · Side effects of drugs annual
  50. New Directions in the Pharmacological Treatment of Food Addiction, Overeating, and Obesity
    Amelia A. Davis, Paula J. Edge, Mark S. Gold · 2014 · Elsevier eBooks
  51. Eating Behavior
    Blundell, John E., Finlayson, Graham, Halford, Jason C. G. · 2009 · Clinical Obesity in Adults and Children
  52. A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
    Sang Min Lee · 2025 · Current Drug Targets
  53. Utilidad de los fármacos antiobesidad en la diabetes mellitus tipo 2
    Johann Elie Aguilar Quevedo, J. Tur, Guillermo Serra, Bartolome G. Burguera · 2010 · Avances en Diabetología
  54. Introduction – Obesity and Food Intake: Basic and Clinical Approaches
    Annette D. de Kloet, Stephen C. Woods · 2009 · Forum of nutrition/Bibliotheca Nutritio et dieta
  55. Obesity: Medical and Surgical Treatment
    Daniele Tassinari, Alessandro Giovanelli, Carmela Asteria · 2021 · Springer eBooks
  56. DIET-INDUCED OBESITY: DOPAMINERGIC AND BEHAVIORAL MECHANISMS AS OUTCOMES AND PREDICTORS
    Vidya Narayanaswami · 2013 · UKnowledge (University of Kentucky)
  57. Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis
    Theodoros Kelesidis, Iosif Kelesidis, Christos Socrates Mantzoros · 2009 · Humana Press eBooks
  58. Adjunctive Therapy, Including Pharmacotherapy
    Dalal Y. Al-Bazz, John P.H. Wilding · 2022 · Wiley eBooks
  59. Pharmacological Management of the Obese Patient
    Donald Schumacher · 2013 · American Journal of Lifestyle Medicine
  60. Pramlintide in the Management of Obesity
    Melissa C. Jones, Heather F. DeBellis, Barefield, Kimberly L · 2010 · Clinical Medicine Reviews in Therapeutics
  61. Experimental models for investigating IAPP regulation of food intake in rats and mice
    Madelene Olsson · 2012 · Figshare
  62. Preguntas y respuestas sobre aspectos generales del tratamiento farmacológico en el paciente obeso
    José Hernández Rodríguez, Manuel Emiliano Licea Puig, Lizet Castelo Elías-Calles · 2013 · DOAJ (DOAJ: Directory of Open Access Journals)
  63. Medicamentos que favorecen la pérdida de peso y el control metabólico en las personas obesas con diabetes
    José Hernández Rodríguez, Manuel Emiliano Licea Puig · 2013
  64. The Renin-Angiotensin System and the Neuroendocrine Regulation of Energy Balance
    E. R. de Kloet, D. Rieg Annette · 2011 · OhioLink ETD Center (Ohio Library and Information Network)
  65. Lixisenatide: A New Glucagon-Like Peptide-1 Agonist
    Christopher W. Ho · 2013 · Journal of Developing Drugs
  66. inhibitory effect kinase 1/2 signaling pathway in amylin's eating Involvement of the extracellular signal-regulated
    Thomas A. Lutz, Catarina Soares Potes, Christina N. Boyle, Peter John Wookey · 2012
  67. Pharmacologie de l'obésité : vers de nouvelles options
    Karine Clément, Olivier Ziegler · 2021 · Elsevier eBooks
  68. Advances in Pharmacological Treatment of Pediatric Obesity
    Michael I. Goran · 2016 · CRC Press eBooks
  69. Amylin analogues
    2015 · Elsevier eBooks
  70. Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats
    Katherine A. Kern, Adrianne M. DiBrog, Emily Demieri, Johnathan T. Przybysz, Stewart D. Clark, Elizabeth G. Mietlicki‐Baase · 2025 · Physiology & Behavior
  71. Synthetic and anti-obesity potential of some fused heterocyclic compounds: a comprehensive update
    Pooja M. Kadu, Utpal Jagdish Dongre, Pankaj V. Ledade, Sami H. Mahmood, Trimurti L. Lambat · 2025 · Chemical Papers
  72. Additional file 2 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
    Anna Thorsø Larsen, Sofie Gydesen, Nina Sonne, Karsdal, Morten Asser, Henriksen, Kim · 2021 · Figshare
  73. Additional file 1 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
    Anna Thorsø Larsen, Sofie Gydesen, Nina Sonne, Karsdal, Morten Asser, Henriksen, Kim · 2021 · Figshare
  74. Implication des neurones exprimant NUCB2/nesfatine-1 dans la régulation de l'homéostasie énergétique
    Marion S. Bonnet · 2013 · theses.fr (ABES)
  75. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
    Sophia L. Fischer, Tito Borner · 2026 · Pharmacological Research
  76. Can Leptin Responsiveness Be Restored in Common Human Obesity?
    J. A. M. J. L. Janssen · 2026 · Lipidology
  77. Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
    Ken Fujioka · 2026 · Nutrition in Clinical Practice
  78. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
    Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Νικόλαος Παπάνας · 2026 · Diabetes Therapy